The application of platelet-rich plasma may be a novel treatment for central nervous system diseases

As a potential biological product, platelet-rich plasma (PRP) has been widely utilized in the areas of oral and maxillofacial reconstruction, bone and soft tissue restoration and wound healing. A recent study reported that the application of PRP on interrupted sciatic nerve could promote remyelinization of peripheral nerve. This renovated a notion that the application of PRP might extend to the nervous system. Most central nervous system (CNS) diseases have a series of common pathological changes in the later period of diseases which induce neurons and glia apoptosis and aggravate neurological dysfunction. It has been demonstrated that the potent restorative function of PRP is mainly based on neurotrophic capacity of preparation rich in growth factors (PRGFs) and scaffolding effect of platelet-rich gel (PRG), all of which could be certified to ameliorate the pathological process of CNS diseases. In view of this, we propose a hypothesis that the application of PRP and its derivatives might provide a novel therapeutic approach for CNS diseases, especially for traumatic brain or spinal cord injury, autoimmune diseases and neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis.